MOMO'S BREAKOUT BOARD

[Pennybuster]

$BSSP The initial deployment for sales of the specific IPF for Cancer indication product and treatment programs to Mexico are now in process with four hospitals positioned and in process of licensing requirements which have been submitted. Canteck is positioned to oversee the development, manufacturing and commercialization processes for our lead product to be the Irreversible Pepsin Fraction (IPF) specific to the Cancer indication, with options for other indications.

"Our transition to the corporate platform for development and deployment of targeted therapeutic immunotherapeutic technology represents an important event in our transition and growth," said Dennis Alexander, CEO of the Company. "Further, the Company welcomes our current and future development with Canteck Pharma, Inc., and working together with our new Board of Directors and Management including Mr. and Mrs. Zhabilov, as the Company looks forward to bringing these novel technological advancements to the forefront initially to Mexico to assist treatment and solutions for specific Cancer treatment and to become available in a cost effective manner to assist the severity of medical needs going unmet."

"The licensing agreement with Reve Technologies, Inc. is very much an important milestone in our goal to develop and commercialize our immune-oncology based IPF treatment as a new therapy for difficult-to-treat tumor indications on a scalable international level initially in Mexico." Said Mr. Harry Zhabilov, Jr. BSc, McS and newly appointed Chief Sciencist of the Company. "We are delighted to have a committed partner and management team and with our missions aligned and look forward to working together to obtain approvals for our IPF Irreversible Pepsin Fraction specific to the Cancer indication, and to bring these much-needed therapeutic options as soon as possible for delivery and availability to Mexico.


Sounds like a lot of UPDATES will be coming fairly quickly
http://marketersmedia.com/reve-acquires-exclusive-license-for-cantecks-ipf-irreversable-pepsin-fraction-specific-to-cancer-indication-only-for-mexico/112197